ArticleRisk analysis : an official publication of the Society for Risk Analysis2025
Impacts of Plant Protection Products on Biodiversity: Limits of Risk Assessment and Avenues to Ground Liability.
Article in Risk analysis : an official publication of the Society for Risk Analysis, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Impacts of Plant Protection Products on Biodiversity: Limits of Risk Assessment and Avenues to Ground Liability.Risk analysis : an official publication of the Society for Risk Analysis · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Plant protection products (PPPs) are intended to protect plants against pests. However, they are also known to contribute unequivocally to the decline of biodiversity due to their negative impact on biological groups such as terrestrial invertebrates, birds, and amphibians. At the intersection of ecotoxicology, social sciences, and law, numerous studies address the discrepancy between the regulatory framework's objectives to protect biodiversity and the actually observed impacts of legally used PPPs. The main reasons put forward are the normalization constraints of ecotoxicity tests and the inability to anticipate effects in the current substance-by-substance risk assessment process given the complexity of multifactorial interactions in the ecosystems and the real conditions of PPP use. Therefore, the greater the consideration given to the systemic complexity of indirect effects, the less possible it is to quantify the contribution of a given cause, in our case, a PPP. This is a core issue in legal disputes regarding the liability of those who develop PPPs, those who use them, as well as decision-makers who approve them. This article explores legal possibilities to better address the missing link between substance-by-substance assessment and authorization processes, and biodiversity protection instruments. The aim is to question the division of roles between scientific expertise, legal disputes, and public policy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.